DC-CIBOK
CIBOK Editorial Committee today announced its establishment and the 1st edition “Cybercrime Investigation Body Of Knowledge” (CIBOK) published work. CIBOK is designed to provide a new standard for law enforcement organizations and enterprises around the globe with knowledge, skills and behaviors required to solve or prevent today’s complex and sophisticated cybercrime. The CIBOK first edition publication is available in English and Japanese.
“As cybercrime evolves from individuals seeking attention and demonstrating their capabilities to organized and syndicated activities of sophisticated goal-oriented actors, it is important to change our focus to understanding the objectives and motivations of the crimes,” said Shane Shook, the chief editor of CIBOK and the chair of Cybercrime Investigation Body Of Knowledge Editorial Committee. “Crime is investigated in terms of means, motives and opportunity to identify perpetrators. Cyber investigations, however, have traditionally focused on tools, techniques and procedures. The CIBOK is intended to weld the best efficiencies of traditional and cyber investigative approaches, and to provide a standard that demonstrates the convergence of societal and corporate understanding of cybercriminal activity. This is step one of what we hope will become coordination and cooperation between public and private sector approaches to addressing global cybercrimes.”
CIBOK describes the needs, background and requirements for security researchers to assist law enforcement, and for corporate risk managers to investigate cybercrimes. The book seeks to fulfill these five objectives:
- Popularize and promote a global commonsense, and consistent, approach to cybercrime investigations.
- Positioning of systematized practices for defining the scope of cybercrime investigations.
- Characterizing through demonstration the content that should be put into practice in cybercrime investigations.
- Providing structural guidance for utilizing CIBOK as an investigation asset to plan, conduct, and review cybercrime investigations.
- Demonstrating the organizational and individual skills and knowledge development needed for cybercrime investigations.
The CIBOK first edition was planned, coordinated and sponsored by Trend Micro, and has been written, reviewed and compiled by 12 experts from various industries as joint forces, including law firms, law enforcement and academia. The CIBOK Editorial Committee will take over copyright and management of CIBOK from Trend Micro.
And a general incorporated association will be established to continue to update CIBOK as public property, and the association will plan to develop a certification program and a related training.
And the CIBOK first edition will be planned to sell from May, 2017. To purchase a copy of the CIBOK book and to learn more about the organization, please visit CIBOK web site.
About CIBOK Editorial Committee
The CIBOK Editorial Committee is organized by 12 experienced legal, judicial and industry leaders, and assigned by a steering committee of industry and legal professionals formed in 2016 with the goal of helping to protect Information and Communication Technology (ICT) assets and operations of society from cybercrime.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170419005066/en/
Contact:
CIBOK Editorial Committee
Yasumoto Masakazu, +81-3-5334-3623
secretariat@cibok.org
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom